ESR1 and breast cancer: These epidrugs [55,66] are a promising strategy for breast cancer therapies as they could restore the estrogen receptor α (ERα) activity in ER- cancer patients, reactivating cancer cell growth in an estrogen-dependent manner resulting sensible to antiestrogenic drugs [51,52,55,58,67-69].